Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-A2DM PET in Metastatic PSCA-Expressing Pancreatic Cancer
NCT07608627Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Dec 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copper Cu 64-DOTA-A2DM in pancreatic cancer (PC), sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 90 days and Dose limiting toxicity. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
copper Cu 64-DOTA-A2DM
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07608627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608627.